Recent Analysts’ Ratings Changes for Editas Medicine (EDIT)

Several analysts have recently updated their ratings and price targets for Editas Medicine (NASDAQ: EDIT):

• 5/10/2026 – Editas Medicine was downgraded by Wall Street Zen from “hold” to “sell”.
• 5/5/2026 – Editas Medicine had its price target raised by Chardan Capital from $3.50 to $4.00. They now have a “buy” rating on the stock.
• 5/2/2026 – Editas Medicine was upgraded by Wall Street Zen from “sell” to “hold”.
• 4/20/2026 – Editas Medicine had its “sell (e+)” rating reaffirmed by Weiss Ratings.
• 4/11/2026 – Editas Medicine was downgraded by Wall Street Zen from “hold” to “sell”.

Editas Medicine is a clinical-stage biotechnology company focused on translating the power of gene editing into a new class of transformative genomic medicines. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company leverages proprietary CRISPR/Cas9 and CRISPR/Cas12a (Cpf1) platforms to develop therapies aimed at correcting disease-causing genetic mutations. Editas Medicine’s research and development efforts span multiple therapeutic areas, including inherited retinal diseases, hemoglobinopathies, and oncology.

The company’s pipeline includes EDIT-101, a lead candidate designed to treat Leber congenital amaurosis type 10 (LCA10), which has entered early-stage clinical trials, and EDIT-301, targeting sickle cell disease and ?-thalassemia using an ex vivo editing approach.